Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:FSNUY
Previous Symbol
CUSIPN/A
Phone49-6172-6080
Debt
Debt-to-Equity Ratio1.04
Current Ratio1.18
Quick Ratio0.92
Price-To-Earnings
Trailing P/E Ratio16.43
Forward P/E Ratio14.53
P/E Growth1.56
Sales & Book Value
Annual Sales$38.28 billion
Price / Sales0.88
Cash Flow$1.7118 per share
Price / Cash8.83
Book Value$11.07 per share
Price / Book1.37
Profitability
EPS (Most Recent Fiscal Year)$0.92
Net Income$2.05 billion
Net Margins5.91%
Return on Equity12.53%
Return on Assets3.85%
Miscellaneous
Employees273,249
Outstanding Shares2,222,460,000
Market Cap$32.51 billion
OptionableNot Optionable
FRESENIUS SE &/S (OTCMKTS:FSNUY) Frequently Asked Questions
What is FRESENIUS SE &/S's stock symbol?
FRESENIUS SE &/S trades on the OTCMKTS under the ticker symbol "FSNUY."
How were FRESENIUS SE &/S's earnings last quarter?
FRESENIUS SE &/S (OTCMKTS:FSNUY) released its earnings results on Wednesday, October, 31st. The company reported $0.23 earnings per share for the quarter. The firm had revenue of $9.52 billion for the quarter. FRESENIUS SE &/S had a return on equity of 12.53% and a net margin of 5.91%. View FRESENIUS SE &/S's Earnings History.
When is FRESENIUS SE &/S's next earnings date?
What is the consensus analysts' recommendation for FRESENIUS SE &/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FRESENIUS SE &/S in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for FRESENIUS SE &/S.
Has FRESENIUS SE &/S been receiving favorable news coverage?
Headlines about FSNUY stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. FRESENIUS SE &/S earned a news impact score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of FRESENIUS SE &/S's key competitors?
Some companies that are related to FRESENIUS SE &/S include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN) and ICU Medical (ICUI).
Who are FRESENIUS SE &/S's key executives?
FRESENIUS SE &/S's management team includes the folowing people:
- Mr. Stephan Sturm, CEO & Chairman of Management Board - Fresenius Management SE (Age 55)
- Ms. Rachel Clare Empey, CFO & Member of Management Board - Fresenius Management SE (Age 42)
- Dr. Francesco De Meo, Member of Management Board - Fresenius Management SE (Age 54)
- Dr. Jürgen Götz, Chief Legal & Compliance Officer & Labor Relations Director and Member of Management Board - GP (Age 54)
- Dr. Ernst Wastler, Member of Management Board - Fresenius Management SE (Age 59)
How do I buy shares of FRESENIUS SE &/S?
Shares of FSNUY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FRESENIUS SE &/S's stock price today?
One share of FSNUY stock can currently be purchased for approximately $15.1150.
How big of a company is FRESENIUS SE &/S?
FRESENIUS SE &/S has a market capitalization of $32.51 billion and generates $38.28 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.92 on an earnings per share basis. FRESENIUS SE &/S employs 273,249 workers across the globe.
What is FRESENIUS SE &/S's official website?
How can I contact FRESENIUS SE &/S?
FRESENIUS SE &/S's mailing address is Else-Kroner-Stra¿e 1, Bad Homburg 2M, 61352. The company can be reached via phone at 49-6172-6080 or via email at [email protected]
MarketBeat Community Rating for FRESENIUS SE &/S (OTCMKTS FSNUY)
MarketBeat's community ratings are surveys of what our community members think about FRESENIUS SE &/S and other stocks. Vote "Outperform" if you believe FSNUY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FSNUY will underperform the S&P 500 over the long term. You may vote once every thirty days.
